Does higher ferritin in MASLD indicate greater hepatic injury and fibrosis risk?

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent condition where elevated iron markers, particularly serum ferritin, frequently emerge as key clinical indicators. High ferritin, often termed metabolic hyperferritinemia, is not merely an innocent bystander but is actively involved in the progression of hepatic pathology.

Clinical and effectiveness evidence

• Histological severity: Clinical cohort studies and biopsy-controlled analyses demonstrate a clear, stepwise association between elevated serum ferritin levels and greater histological severity in MASLD. Elevated ferritin levels independently predict advanced disease, including non-alcoholic steatohepatitis (NASH/MASH).
• Fibrosis risk: High ferritin serves as a strong independent biomarker for advanced hepatic fibrosis. Multi-variable analyses show that patients with elevated ferritin have significantly higher odds of advanced fibrosis (fibrosis stages F3 and F4) compared to those with normal range ferritin.
• Liver injury markers: Increased serum ferritin levels consistently correlate with elevated serum aminotransferases (ALT and AST), reflecting active hepatocyte injury and necrosis.

Mechanistic explanations

• Oxidative stress and lipid peroxidation: Excess intracellular iron resulting from high ferritin levels promotes the Fenton reaction, generating highly reactive hydroxyl radicals. This induces profound oxidative stress, lipid peroxidation of cell membranes, mitochondrial dysfunction, and ultimately drives hepatocytes toward ferroptosis (an iron-dependent form of programmed cell death).
• Direct stellate cell activation: Beyond serving as an iron storage molecule, extracellular ferritin acts directly as a pro-inflammatory cytokine. Ferritin binds to specific receptors on hepatic stellate cells (HSCs), triggering an iron-independent signaling cascade involving the transcription factor NF-kB.
• Fibrotic cascade: Activated HSCs transdifferentiate into proliferative, contractile myofibroblasts. This activation drives the release of profibrogenic cytokines, such as transforming growth factor-beta 1 (TGF-β1), leading to massive collagen deposition and progressive extracellular matrix remodeling (fibrogenesis).

Bottom line

In patients with MASLD, elevated serum ferritin is a robust, clinically validated biomarker and pathogenic driver of both hepatic injury and advanced fibrosis risk. This risk is driven by a combination of iron-mediated oxidative stress and direct, pro-inflammatory activation of hepatic stellate cells. For a 53-year-old male with MASLD, monitoring ferritin levels is highly valuable for risk stratification and assessing the likelihood of progressive liver fibrosis.